Annual Accounts Payable
$11.82 M
-$5.88 M-33.22%
31 December 2023
Summary:
Halozyme Therapeutics annual accounts payable is currently $11.82 million, with the most recent change of -$5.88 million (-33.22%) on 31 December 2023. During the last 3 years, it has risen by +$9.89 million (+512.86%). HALO annual accounts payable is now -33.22% below its all-time high of $17.69 million, reached on 31 December 2022.HALO Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$12.40 M
-$3.03 M-19.65%
30 September 2024
Summary:
Halozyme Therapeutics quarterly accounts payable is currently $12.40 million, with the most recent change of -$3.03 million (-19.65%) on 30 September 2024. Over the past year, it has dropped by -$6.92 million (-35.82%). HALO quarterly accounts payable is now -35.82% below its all-time high of $19.32 million, reached on 30 September 2023.HALO Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -33.2% | -35.8% |
| 3 y3 years | +512.9% | +273.2% |
| 5 y5 years | +189.7% | +187.4% |
HALO Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -33.2% | +666.8% | -35.8% | +879.3% |
| 5 y | 5 years | -33.2% | +666.8% | -35.8% | +2763.3% |
| alltime | all time | -33.2% | +756.3% | -35.8% | >+9999.0% |
Halozyme Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $12.40 M(-19.7%) |
| June 2024 | - | $15.43 M(+15.8%) |
| Mar 2024 | - | $13.32 M(+12.8%) |
| Dec 2023 | $11.82 M(-33.2%) | $11.82 M(-38.8%) |
| Sept 2023 | - | $19.32 M(+90.9%) |
| June 2023 | - | $10.12 M(+16.4%) |
| Mar 2023 | - | $8.70 M(-50.9%) |
| Dec 2022 | $17.69 M(+1048.2%) | $17.69 M(-2.6%) |
| Sept 2022 | - | $18.17 M(+48.5%) |
| June 2022 | - | $12.23 M(+866.2%) |
| Mar 2022 | - | $1.27 M(-17.8%) |
| Dec 2021 | $1.54 M(-20.1%) | $1.54 M(-53.6%) |
| Sept 2021 | - | $3.32 M(-27.2%) |
| June 2021 | - | $4.56 M(+752.9%) |
| Mar 2021 | - | $535.00 K(-72.3%) |
| Dec 2020 | $1.93 M(-70.0%) | $1.93 M(+345.3%) |
| Sept 2020 | - | $433.00 K(-89.4%) |
| June 2020 | - | $4.07 M(-51.1%) |
| Mar 2020 | - | $8.32 M(+29.3%) |
| Dec 2019 | $6.43 M(+57.7%) | $6.43 M(+49.1%) |
| Sept 2019 | - | $4.31 M(-65.4%) |
| June 2019 | - | $12.47 M(+204.9%) |
| Mar 2019 | - | $4.09 M(+0.2%) |
| Dec 2018 | $4.08 M(-48.7%) | $4.08 M(+22.5%) |
| Sept 2018 | - | $3.33 M(-46.2%) |
| June 2018 | - | $6.19 M(+70.5%) |
| Mar 2018 | - | $3.63 M(-54.4%) |
| Dec 2017 | $7.95 M(+122.1%) | $7.95 M(+91.4%) |
| Sept 2017 | - | $4.15 M(-26.5%) |
| June 2017 | - | $5.65 M(+83.5%) |
| Mar 2017 | - | $3.08 M(-13.9%) |
| Dec 2016 | $3.58 M(-20.5%) | $3.58 M(-22.9%) |
| Sept 2016 | - | $4.64 M(+27.2%) |
| June 2016 | - | $3.65 M(-41.2%) |
| Mar 2016 | - | $6.21 M(+38.1%) |
| Dec 2015 | $4.50 M(+49.8%) | $4.50 M(+1.4%) |
| Sept 2015 | - | $4.44 M(+7.2%) |
| June 2015 | - | $4.14 M(+25.4%) |
| Mar 2015 | - | $3.30 M(+9.9%) |
| Dec 2014 | $3.00 M | $3.00 M(-30.8%) |
| Sept 2014 | - | $4.34 M(+11.0%) |
| June 2014 | - | $3.91 M(-54.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $8.66 M(+176.2%) |
| Dec 2013 | $3.13 M(+38.0%) | $3.13 M(-43.9%) |
| Sept 2013 | - | $5.59 M(-25.3%) |
| June 2013 | - | $7.48 M(+159.3%) |
| Mar 2013 | - | $2.88 M(+27.0%) |
| Dec 2012 | $2.27 M(-69.9%) | $2.27 M(-35.6%) |
| Sept 2012 | - | $3.53 M(+69.0%) |
| June 2012 | - | $2.09 M(-30.7%) |
| Mar 2012 | - | $3.01 M(-60.2%) |
| Dec 2011 | $7.56 M(+97.8%) | $7.56 M(+519.5%) |
| Sept 2011 | - | $1.22 M(-29.6%) |
| June 2011 | - | $1.73 M(+19.3%) |
| Mar 2011 | - | $1.45 M(-62.0%) |
| Dec 2010 | $3.82 M(+35.5%) | $3.82 M(+109.0%) |
| Sept 2010 | - | $1.83 M(-13.0%) |
| June 2010 | - | $2.10 M(-50.6%) |
| Mar 2010 | - | $4.25 M(+50.7%) |
| Dec 2009 | $2.82 M(-57.7%) | $2.82 M(-44.9%) |
| Sept 2009 | - | $5.12 M(-5.7%) |
| June 2009 | - | $5.43 M(+2.4%) |
| Mar 2009 | - | $5.30 M(-20.5%) |
| Dec 2008 | $6.67 M(+118.2%) | $6.67 M(+61.0%) |
| Sept 2008 | - | $4.14 M(+47.1%) |
| June 2008 | - | $2.81 M(-17.2%) |
| Mar 2008 | - | $3.40 M(+11.2%) |
| Dec 2007 | $3.06 M(+51.5%) | $3.06 M(+11.9%) |
| Sept 2007 | - | $2.73 M(+76.3%) |
| June 2007 | - | $1.55 M(+44.4%) |
| Mar 2007 | - | $1.07 M(-46.9%) |
| Dec 2006 | $2.02 M(+46.2%) | $2.02 M(+41.3%) |
| Sept 2006 | - | $1.43 M(+29.1%) |
| June 2006 | - | $1.11 M(-31.8%) |
| Mar 2006 | - | $1.62 M(+17.5%) |
| Dec 2005 | $1.38 M(-7.2%) | $1.38 M(-4.2%) |
| Sept 2005 | - | $1.44 M(+1.9%) |
| June 2005 | - | $1.41 M(-20.1%) |
| Mar 2005 | - | $1.77 M(+18.9%) |
| Dec 2004 | $1.49 M | $1.49 M(-22.7%) |
| Sept 2004 | - | $1.92 M(+61.4%) |
| June 2004 | - | $1.19 M(+87.0%) |
| Mar 2004 | - | $637.30 K(>+9900.0%) |
| Mar 2002 | - | $2900.00 |
FAQ
- What is Halozyme Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual accounts payable year-on-year change?
- What is Halozyme Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly accounts payable year-on-year change?
What is Halozyme Therapeutics annual accounts payable?
The current annual accounts payable of HALO is $11.82 M
What is the all time high annual accounts payable for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual accounts payable is $17.69 M
What is Halozyme Therapeutics annual accounts payable year-on-year change?
Over the past year, HALO annual accounts payable has changed by -$5.88 M (-33.22%)
What is Halozyme Therapeutics quarterly accounts payable?
The current quarterly accounts payable of HALO is $12.40 M
What is the all time high quarterly accounts payable for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly accounts payable is $19.32 M
What is Halozyme Therapeutics quarterly accounts payable year-on-year change?
Over the past year, HALO quarterly accounts payable has changed by -$6.92 M (-35.82%)